To check effectiveness of oral Ketamine as an analgesic adjuvant to oral Morphine, Amitriptyline and Pregabalin on cancer pain relief, opioid analgesic consumption and functional improvement in cancer patients

Not Applicable

• Registration Number: CTRI/2020/02/023296
• Lead Sponsor: HCG Cancer Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Age 18 to 75 years

Patients with malignant solid tumors

Patients with cancer pain of Numerical Rating Scale greater than or equal to 4, not controlled by Oral Morphine 60 mg per day and, neuropathic pain medications Oral Amitriptyline 50 mg per day and Oral Pregabalin 150 mg per day

Exclusion Criteria

Patients who had received Ketamine for chronic pain within 6 months

Comorbidities contraindicating the use of Ketamine(e.g. history of hypertension or on antihypertensive therapy, history of heart failure, history of angina & myocardial infarction in last 6 weeks, aneurysm, cerebral trauma)

Patient with history of substance use disorder

Patients not able to take oral drugs

Patients with coexisting liver or renal disease

Patients who received radiotherapy or surgical therapy within past 2 months

Patients having pain as a side effect of chemotherapy

Patients with brain metastases of cancer

Study & Design

• Study Type: Interventional
• Study Design: Not specified